Solid-tumor biomarker
Nasopharyngeal Carcinoma NPC-REAAD
A diagnostic biomarker offering associated with nasopharyngeal carcinoma on the former site.
Product overview
What it is.
- Restalyst NPC-REAAD EBV EA-IgA ELISA: an in-vitro diagnostic for the qualitative and semi-quantitative detection of IgA antibodies in human serum or plasma, to aid in the diagnosis of nasopharyngeal carcinoma.
- Uses highly specific Epstein-Barr virus proteins, produced with recombinant DNA technology, to detect the patient’s Early Antigen (EA) IgA response.
- Reports a positive or negative risk result using an arbitrary measurement scale called REAAD-units (RU).
How it works
Recombinant NPC antigens are coated on the microwells. Human IgA against EBV EA proteins binds the antigens; after washing, HRP-conjugated secondary antibodies bind the complexes and a TMB substrate turns into a colour signal proportional to the amount present. Wells are read on any suitable spectrophotometer or ELISA reader.
Specifications
Key figures.
The source graphic renders sensitivity and specificity as “960%” and “940%”; they are shown here as 96.0% and 94.0% and must be confirmed.
- Sensitivity
- 96.0%
- Specificity
- 94.0%
- Inter-assay precision
- 2.99% – 3.65%
- Intra-assay precision
- 3.15% – 3.17%
- Sample type
- Serum / plasma
- Assay duration (approx.)
- 1.5 hours
- Patient sample volume
- <10 µL
- Shelf life
- 13 months
- Certification
- CE-IVD certified; HSA (Singapore) and MDA (Malaysia) registered
Portfolio information
From the original portfolio.
The legacy description references an EBV EA-IgA ELISA assay using serum or plasma. Current specifications require confirmation.
This page preserves the former site’s product information for review. It does not establish current Canadian availability, approved indications, performance, or prescribing information. Request verified documentation before relying on it.
Request verified informationExplore this area